The interchangeability of original tumor necrosis factor- α inhibitors and biosimilars in rheumatology: experience in replacing original infliximab with Flammagis for ankylosing spondylitis

類似資料

• The effectiveness of switching from an originator biological agent to its biosimilar, or vice versa, for ankylosing spondylitis in real clinical practice
  著者:: K. V. Sakharova, 等
  出版事項: (2020-11-01)
• INFLIXIMAB-INDUCED LUPUS-LIKE SYNDROME IN A FEMALE PATIENT WITH RHEUMATOID ARTHRITIS (A CASE REPORT): AN ACCIDENT OR REGULARITY?
  著者:: Yu. V. Muravyev, 等
  出版事項: (2017-09-01)
• Comparative efficacy and safety of infliximab biosimilar (BCD-055) and innovator infliximab in patients with ankylosing spondylitis (results of international, multiple-center, double-blind phase I and phase III clinical studies)
  著者:: D. E. Karateev, 等
  出版事項: (2017-09-01)
• Clinical features of ankylosing spondylitis in patients with secondary AA amyloidosis
  著者:: D. G. Rumyantseva, 等
  出版事項: (2020-09-01)
• Experience with long-term infliximab therapy in patients with ankylosing spondylitis
  著者:: Oksana Alekseevna Rumyantseva, 等
  出版事項: (2010-12-01)